Relapsed data are uncompetitive, but the front-line PACC-mutant space offers hope.
ApexOnco Front Page
Recent articles
Cross-licensing pact brings in SKB105, and hands off China rights to CR-001 before first-in-human studies.
Pivotal data set the stage for slightly delayed US accelerated approval filing.
The latest projects newly into human trials include BNT3212.
But results come from a curated dataset, with no in-trial comparator.
Global data are in the same ballpark as Chinese results presented earlier this year.
A common mutation comes into play for PRMT5 inhibition.
Early data with IDE849 look better those with Zai’s zocilurtatug pelitecan.
